CN108541952A - A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity - Google Patents
A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity Download PDFInfo
- Publication number
- CN108541952A CN108541952A CN201810313219.5A CN201810313219A CN108541952A CN 108541952 A CN108541952 A CN 108541952A CN 201810313219 A CN201810313219 A CN 201810313219A CN 108541952 A CN108541952 A CN 108541952A
- Authority
- CN
- China
- Prior art keywords
- casein
- composition
- alpha
- antiallergy
- strengthen immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000036039 immunity Effects 0.000 title claims abstract description 18
- 208000007502 anemia Diseases 0.000 title claims abstract description 13
- 230000003266 anti-allergic effect Effects 0.000 title claims description 11
- 102000011632 Caseins Human genes 0.000 claims abstract description 68
- 108010076119 Caseins Proteins 0.000 claims abstract description 68
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 34
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 34
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 33
- 235000021240 caseins Nutrition 0.000 claims abstract description 27
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 23
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 23
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 23
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 23
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 23
- 229940021722 caseins Drugs 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 235000021249 α-casein Nutrition 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 235000019419 proteases Nutrition 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- 235000021119 whey protein Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 10
- 210000004251 human milk Anatomy 0.000 abstract description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 6
- 239000005018 casein Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 229940088592 immunologic factor Drugs 0.000 abstract description 3
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000167880 Hirundinidae Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007674 genetic toxicity Effects 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710126949 Lysin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The object of the present invention is to provide the alimentation composition of a kind of casein containing α, γ caseins, k caseins, alpha lactalbumin and lactoferrin and its applications in ordinary food, health food or drug, and provide a kind of alpha lactalbumin preparation method.The alimentation composition can effectively improve infant immunity and anti-infection ability, close to human milk immune factor, and can prevent hypoferric anemia.
Description
Technical field
It is more specifically related to the present invention relates to a kind of antiallergy and with the composition for preventing anaemia and strengthen immunity
And a kind of alimentation composition containing alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin and its general
Application in logical food, health products or drug.
Background technology
Due to the later ability mature of the immune system of infant, so its immunity and resistance are all weaker, anti-sense
The ability of dye is poor, many infants can all occur gastrointestinal function, immune function are not perfect, Abwehrkraft des Koepers is weaker, digestion work(
It can disorder and infectious diseases etc..This not only hinders the growth and development of baby's physique, to the hair of baby's intelligence cognition
It educates, the development of emotion sociability all brings different degrees of influence.
In the market all there is this in the existing product such as colostrum, antibiotic drug etc. for infant's resistance building
The such drawback of sample：If colostrum contains hormone, sex premature may be caused；Antibiotics, which are taken for a long time, has certain poison is secondary to make
With especially having detrimental effect to infant's normal development.
Lactoferrin (lactoferrin, abbreviation LF) is a kind of natural glycoprotein with immune function, by turning iron egg
White transformation, also someone is called " Lactoferrin ", is primarily present in breast milk and cow's milk.Content of the lactoferrin in human milk
It is very rich, up to 7g/L especially in colostrum.It can be declined with its ripe content of milk, be during suckling lg/L
Left and right.Content is then relatively low in cow's milk, is typically only 0.1g/L, and content is much lower compared with breast milk.
It includes a large amount of essential amino acid, the high-quality protein with very high nutritive value that alpha lactalbumin, which is a kind of,.α-
The property that lactalbumin is easy to digest, easily absorbs is similar to breast milk proteins.In addition alpha lactalbumin includes a large amount of tryptophan energy
Memory is enough improved, the feeling of depression is reduced, allows the mood of baby is more stable, sleeps more fragrant and more sweet.
Alpha lactalbumin is the indispensable nutrition of baby.Alpha lactalbumin is the protein that content is most in breast milk, is accounted for total
The 27% of protein, containing abundant tryptophan, be adjust baby sleep, appetite and mood important nutrient
Experiment shows that alpha lactalbumin is easier to be digested and assimilated by baby, allows baby to keep good appetite, to promote physique
It grows up healthy and sound.Contain abundant tryptophan in alpha lactalbumin.Tryptophan be adjust baby sleep, mood important nutrient.
Meanwhile the good tolerance of alpha lactalbumin allows baby to be not easy to cry and scream, and helps to cultivate good mood.These can be helped
The good behavioral development of baby.
Alpha-casein is the major protein of mammal, does not have alpha-casein in human milk.Casein is both amino to child
The source of acid and the source of calcium and phosphorus, casein form curdled milk to digest under one's belt.
K- casein k- casein are typically a kind of phosphoprotein containing a small amount of phosphate of cow's milk glandular secretion
One of (phasphuprqtein).Confirm that .K caseins are the natural substrates of renin.In its natural state, K- junket egg from
It is the important factor for making milk protect milkiness liquid status to be stablized.
Invention content
The object of the present invention is to provide one kind containing alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and newborn iron
The alimentation composition of albumen and its application in ordinary food, health food or drug.The alimentation composition can be carried effectively
High infant immunity and anti-infection ability close to human milk immune factor, and can prevent hypoferric anemia.
The technical scheme is that：A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity, including
Alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin, alpha-casein, γ-junket in the composition
Albumen, k- caseins, alpha lactalbumin and lactoferrin weight percent be 1-99:1-99:1-99:1-99：1-99.
Preferably, alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and newborn iron egg in the composition
White ratio is 1-49:1-49:1-49:1-49:1-49.
In order to achieve the above object, the present invention provides a kind of alpha lactalbumin preparation method, the preparation method includes as follows
Step：
(1) aqueous whey protein solution is prepared；
(2) protease is added into aqueous whey protein solution to be hydrolyzed, wherein being that neutral proteinase hydrolysis is first added to hydrolysis
Degree reaches 6~8%, adds flavor protease cohydrolysis to degree of hydrolysis and reaches 10~25%, terminates hydrolysis；
(3) it is concentrated, dry to terminate the solution after hydrolysis, obtains the alpha lactalbumin powder.
The dosage form of alimentation composition of the present invention is solid beverage, tablet, soft capsule, hard capsule, microcapsules, granule, drink
Material, pulvis or dairy products, including above-mentioned any one of them alimentation composition, the alimentation composition accounts for the total matter of finished product
The 1%-100% of amount.Preferably, the alimentation composition accounts for the 10%-50% of finished product gross mass.
The above-mentioned alimentation composition containing alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin,
Application in terms of antiallergy, strengthen immunity and prevention hypoferric anemia.
Beneficial effects of the present invention：The drawbacks of according to existing product, particular for infant crowd, the present invention provides one
Alimentation composition of the kind comprising alpha-casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin, described contains α-
Casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin alimentation composition in, include the α-of certain content
Casein, gamma-casein, k- caseins, alpha lactalbumin and lactoferrin, close to human milk immune factor.By supplementing in vitro
Close to the immune essence of breast milk, shows the effect for preferably effectively improving infant's resistance and immunity, effectively improve such
The immunity of crowd.The alimentation composition has safety good, and effect is good and takes for a long time without any side effects excellent
Gesture.The alimentation composition can be used as ordinary food, health products or drug, be suitable for being used for a long time, it will bring well
Social benefit.
Specific implementation mode
Below by following embodiment, the invention will be further described, it will be helpful to understand the present invention, but and unlimited
Present disclosure processed.
Embodiment 1 (hard capsule)
By alpha-casein 1%, gamma-casein 2%, k- caseins 3%, alpha lactalbumin 30%, lactoferrin powder 99%；By than
Example after mixing, with capsule filling machine be filled to get.
Embodiment 2 (pulvis)
By alpha-casein 1%；Gamma-casein 1.5%；K- caseins 4%；Alpha lactalbumin 35%；Lactoferrin powder 80%；Dimension
Raw element E 0.2%；Fruit vegetable powder 4.6%；Xylo-oligosaccharide 35%；After mixing in proportion, dispensed to get.
Embodiment 3 (granule)
By alpha-casein 1%；Gamma-casein 3%；K- caseins 5%；Alpha lactalbumin 40%；Lactoferrin powder 60%；Lactose
31%；After mixing in proportion, through granulation, after dry, then dispensed to get.
Embodiment 4 (solid beverage)
By alpha-casein 1%；Gamma-casein 2%；K- caseins 1%；Alpha lactalbumin 50%；Lactoferrin powder 99%；；It is low
Xylan 15%；Oligoisomaltose 14%；Glucose 29%；Milk powder 25%；It after mixing in proportion, is dispensed, i.e.,
.
Embodiment 5 (tablet)
By alpha-casein 2%；Gamma-casein 6%；K- caseins 9%；Alpha lactalbumin 60%；Lactoferrin powder 99%；It is oligomeric
Galactolipin 14%；Maltodextrin 68.4%；After mixing in proportion, through granulation, carried out again after dry tabletting to get.
Embodiment 6 (dairy products)
By alpha-casein 1%；Gamma-casein 5%；K- caseins 9%；Alpha lactalbumin 70%；Lactoferrin powder 88%；It is full-cream
Milk powder 19.5%；Water 79.3%；After mixing in proportion, dispense to obtain the final product.
Embodiment 7 (beverage)
By alpha-casein 1%；Gamma-casein 4%；K- caseins 3%；Alpha lactalbumin 36%；Lactoferrin powder 78%；Dimension life
Plain C 0.4%；VitaminB10 .15%；Vitamin B2 0.19%；Vitamin B6 0.17%；Glucose 15%；Milk powder 19%；
Purified water 88.23%；After mixing makes to be completely dissolved uniformly in proportion, then dispensed to get.
Experiment
1, experiment material
Sample：Alpha-casein, gamma-casein, k- caseins, alpha lactalbumin, lactoferrin powder are by sample made from embodiment 1
Product.
Experimental animal：Quality is the mouse of 18~22g or so, and 90, male and female dual-purpose is randomly divided into 3 big groups, per big group
3 groups are randomly divided into again to be tested.
Test method：Be recommended as 0.01g/kg according to human body taking dose, thus set composition is low, high dose as
0.05g/kg and 0.2g/kg (5 times, 20 times that are respectively equivalent to human body recommended amounts), sample is made into after by test solution, by small
Mouse gavage, control group gavage is with isometric distilled water, once a day, continuous 30 days.
2, strengthen immunity function evaluation methods
The mouse spleen lymphocyte transformation experiment induced by ConA：Mtt assay：Serum hemolysin measures：Hemagglutination Method；Antibody tormation
Cell detection：Jerne improves slide methods；Turnover of Mouse Peritoneal Macrophages swallows chicken red blood cell experiment：Half intracorporal method.
3, antiallergy, strengthen immunity and prevention hypoferric anemia functional evaluation result
The influence that 3.1 compositions generate mice serum hemolysin
| Dosage | Number of animals/only | Optical density difference（X±s） |
| Control group | 10 | 189.27±11.90 |
| 0.05 | 10 | 202.00±9.19 |
| 0.2 | 10 | 222.00±11.19 |
Influence of 1 composition of table to mice serum blood lysin antibody product
It notes * and indicates P ＜ 0.05 compared with the control group
Low as shown in Table 1, high dose group is compared with control group mice, the significant difference of antibody product (P ＜ 0.05).
Influence of 3.2 compositions to mouse antibodies cellulation
| Dosage | Number of animals/only | Antibody-producting cell number/106（X±s） |
| Control group | 10 | 202.18±84.03 |
| 0.05 | 10 | 317.50±97.53 |
| 0.2 | 10 | 387.50±115.21 |
Influence of 2 composition of table to mouse antibodies cellulation
It notes * and indicates P ＜ 0.01 compared with the control group
Low as shown in Table 2, high dose group is compared with control group mice, significant difference (the P ＜ of antibody-producting cell number
0.01)
Influence of 3.3 compositions to Turnover of Mouse Peritoneal Macrophages chicken red blood cell ability
| Dosage | Number of animals/only | Phagocytic percentage/%（X±s） | Phagocytic index（X±s） |
| Control group | 10 | 30.64±2.48 | 1.00±0.10 |
| 0.05 | 10 | 39.65±3.09 | 1.14±0.11 |
| 0.2 | 10 | 39.24±3.89 | 1.34±0.19 |
3 composition of table swallows Turnover of Mouse Peritoneal Macrophages the influence of chicken red blood cell ability
It notes * and indicates P ＜ 0.05 compared with the control group
Low as shown in Table 3, high dose group is compared with control group mice, phagocytic percentage of the peritoneal macrophage to chicken red blood cell
The significant difference of phagocytic index (P ＜ 0.05).
3.4 functional evaluation results
By above-mentioned the experimental results showed that：In the experiment of mice serum hemolysin test, antibody-producting cell detection experiment, mouse abdomen
Chamber macrophage swallows in chicken red blood cell experiment, the significant difference of result.According to evaluation criterion it is believed that composition has increasing
The function of strong immunity.
2 composition Toxicological evaluations
2.1 material
Sample：Alpha-casein, gamma-casein, k- caseins, alpha lactalbumin, lactoferrin powder are by sample made from embodiment 1
Product.Experimental animal：Cleaning grade Kunming mouse and SD rats.
2.2 Toxicological evaluation methods
Acute toxicity testing (MTD methods), Genetic toxicity and rat are carried out to composition and feed experiment within 30 days.It is wherein hereditary
Toxicity test includes Ames experiments, mouse bone marrow polychromatic erythrocytes micronucleus test and mouse sperm deformity experiment.
2.3 Toxicological evaluation results
Acute oral toxicity is tested：The acute oral MTD of SD rats and Kunming mouse is all higher than 20g/kg.bw and belongs to practical
Non-toxic type.
Genetic toxicity Ames experiments：Mouse bone marrow polychromatic erythrocytes micronucleus test and mouse sperm deformity experiment 3
Item Genetic toxicity result is feminine gender, shows this product without mutagenesis and teratogenesis.
Rat feeds experiment in 30 days：Maximum dose level is 100 times of human body recommended amounts, and this product does not cause rat to be integrally good for
The anomalous variation of the items important indicator such as health situation biochemical functions and organ-tissue morphology.
What has been described above is only a preferred embodiment of the present invention, it is noted that for common skill in the art
For art personnel, under the premise of not departing from core technical features of the present invention, several improvement can also be made, these improve and
Retouching also should be regarded as protection scope of the present invention.
Claims (4)
1. a kind of antiallergy and the composition with prevention anaemia and strengthen immunity, it is characterized in that, including alpha-casein, γ-
Casein, k- caseins, alpha lactalbumin and lactoferrin, alpha-casein in the composition, gamma-casein, k- caseins,
The weight percent of alpha lactalbumin and lactoferrin is 1-99:1-99:1-99:1-99:1-99.
2. antiallergy according to claim 1 and the composition with prevention anaemia and strengthen immunity, which is characterized in that
Alpha lactalbumin preparation method includes the following steps：
(1) aqueous whey protein solution is prepared；
(2) protease is added into aqueous whey protein solution to be hydrolyzed, wherein being that neutral proteinase hydrolysis is first added to hydrolysis
Degree reaches 6~8%, adds flavor protease cohydrolysis to degree of hydrolysis and reaches 10~25%, terminates hydrolysis；
(3) it is concentrated, dry to terminate the solution after hydrolysis, obtains the alpha lactalbumin powder.
3. antiallergy according to claim 1 and the composition with prevention anaemia and strengthen immunity, which is characterized in that
The combination dosage form is solid beverage, tablet, soft capsule, hard capsule, microcapsules, granule, beverage, pulvis and breast system
Product.
4. antiallergy according to claim 1 and the composition with prevention anaemia and strengthen immunity, which is characterized in that
Application in terms of antiallergy, strengthen immunity and hypoferric anemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810313219.5A CN108541952A (en) | 2018-04-10 | 2018-04-10 | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810313219.5A CN108541952A (en) | 2018-04-10 | 2018-04-10 | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108541952A true CN108541952A (en) | 2018-09-18 |
Family
ID=63514503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810313219.5A Pending CN108541952A (en) | 2018-04-10 | 2018-04-10 | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108541952A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194750A (en) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | Nutritional composition for inducing satiety, better sleep and/or limiting nighttime arousal in infants or young children |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102551073A (en) * | 2012-02-22 | 2012-07-11 | 浙江康恩贝健康产品有限公司 | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition |
| CN103442592A (en) * | 2010-12-29 | 2013-12-11 | Mjn美国控股有限责任公司 | Use of nutritional compositions including lactoferrin in stimulating immune cells |
-
2018
- 2018-04-10 CN CN201810313219.5A patent/CN108541952A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103442592A (en) * | 2010-12-29 | 2013-12-11 | Mjn美国控股有限责任公司 | Use of nutritional compositions including lactoferrin in stimulating immune cells |
| CN102551073A (en) * | 2012-02-22 | 2012-07-11 | 浙江康恩贝健康产品有限公司 | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition |
Non-Patent Citations (1)
| Title |
|---|
| 于新等: "《天然食品添加剂》", 31 March 2014, 中国轻工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194750A (en) * | 2018-12-21 | 2021-07-30 | 雀巢产品有限公司 | Nutritional composition for inducing satiety, better sleep and/or limiting nighttime arousal in infants or young children |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Getaneh et al. | Review on goat milk composition and its nutritive value | |
| CN102551073B (en) | Nutritional composition containing alpha-lactoalbumin and lactoferrin and application of nutritional composition | |
| US4834974A (en) | Immunologically active whey fraction and recovery process | |
| CN103053695B (en) | Female formula goat milk powder and preparation method thereof | |
| MX2007010094A (en) | Oligosaccharide mixture. | |
| CN107771945A (en) | A kind of formula milk and its manufacture method for helping to improve middle-aged and old sleep qualities | |
| CN103621633A (en) | Infant series yak milk formula milk powder and preparation method thereof | |
| CN108813632A (en) | A kind of alimentation composition and its application containing lactoferrin | |
| CN103070242A (en) | Formula goat milk powder for pregnant women and preparation method of formula goat milk powder | |
| CN106720456A (en) | Solid beverage composition containing WPC and preparation method thereof | |
| Çelik | Whey every aspect | |
| CN102524420A (en) | Dry-process production method for immune system formula milk powder | |
| CN108541952A (en) | A kind of antiallergy and with the composition for preventing anaemia and strengthen immunity | |
| CN112715672A (en) | Oligosaccharide mother-emulsified infant formula milk and preparation method thereof | |
| CN101014253A (en) | Human milk fortifiers and methods for their production | |
| US5198213A (en) | Method of disease treatment utilizing an immunologically whey fraction | |
| CN101248819B (en) | Preparation of IgG riched-containing bovine colostrum | |
| Sydney et al. | Colostrum new insights: products and processes | |
| CN109452369A (en) | It is a kind of to receive cream and its preparation method and application containing milk powder | |
| CN108064939A (en) | A kind of preparation method of corn oligopeptide powder acidified milk alcohol-decomposing beverage | |
| KR101309089B1 (en) | A milk intensifled protein and making method thereof | |
| CN114532406A (en) | Formula milk powder for improving human immunity and preparation method and application thereof | |
| CN110651940A (en) | Marine fishbone collagen oligopeptide powder solid beverage and preparation method thereof | |
| CN104939098A (en) | Health food capable of enhancing bone immunity and supplementing and locking calcium and preparation method of health food | |
| AL-Moosawi et al. | Camel milk as an integrated food and its physical and chemical properties with therapeutic characteristics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180918 |